Atavistik Bio announced a $40 million extension to its Series B, bringing total Series B financing to $160 million to support clinical development of its lead allosteric programs, including a candidate for hereditary hemorrhagic telangiectasia (HHT). The company aims to advance its HHT program into clinical trials where no approved targeted therapies currently exist. Atavistik’s financing round—backed by strategic investors and life‑science VCs—will fund trial start‑up activities and expand the company’s translational capabilities. Management framed the capital as essential to accelerate proof‑of‑concept work in rare bleeding disorders and myelofibrosis indications. The raise highlights sustained investor appetite for precision approaches to hematologic and vascular disorders and underscores the market’s willingness to fund rare‑disease programs with clear unmet need and plausible pathobiology.